C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027
Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026
Excerpt from the Press Release:
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM).
“Initiating the Phase 2 MOMENTUM trial, which builds upon the compelling anti-myeloma activity and differentiated safety profile established in the Phase 1 trial, is a critical step for cemsidomide to become a foundational therapy for multiple myeloma patients, who are in need of a safe, oral, and convenient treatment option,” said Len Reyno, chief medical officer of C4 Therapeutics. “With this milestone accomplished, we are also on track to initiate the Phase 1b trial of cemsidomide in combination with elranatamab in the second quarter, as we continue to advance our regulatory strategy that could deliver two accelerated approval paths in multiple myeloma.”
The Phase 2 MOMENTUM trial is an open-label, single-arm, multicenter study to assess anti-myeloma activity and further characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of cemsidomide, an oral IKZF1/3 degrader, in combination with dexamethasone in RRMM patients for the fourth line or later. The trial will enroll approximately 100 patients to evaluate cemsidomide at the 100 µg dose level. Cemsidomide is administered with a daily dosing schedule of 14 days on and 14 days off, and dexamethasone is dosed once a week.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?